Exploratie en ontwikkeling van combinatie immuuntherapie als behandeling voor uteriene tumoren
Year: 2014
Type: dissertation
Abstract: Although current treatments are often curative for uterine cancer when it is diagnosed in an early stage, with a 5-year survival rate of around 80 %, these treatments are often no longer effective in case of far-advanced disease. The mean survival rate for stage III uterine tumors is 57.8 %, while for stage IV, this number decreases even further to a mere 22.8 %. Consequently, additional treatments are needed.The main focus of the current project was to further develop an autologous dendritic cell-based vaccine for uterine tumors. The initial vaccine using WT1 mRNA loaded monocyte-derived DC, showed an immunological response in 5/8 patients and a transient clinical response in 2/8 patients. In the current study, the vaccine was further improved and extended.The first objective was to identify additional antigenic targets to include in the vaccine. We selected 6 different antigens, MAGE-A3, BORIS, MUC1, Sp17, hTERT and survivin, for validation using immunohistochemistry as well as qRT-PCR. In addition, to verify the immunogenicity of these antigens, spontaneous ex vivo T cell responses to these antigens were analyzed. From these analyses, we found that survivin was the best suitable target to proceed with.In addition to adding a new target antigen to the DC vaccine, we aimed to further improve the functional characteristics of the DC used in the vaccine. To this end, an optimal protocol for the generation of monocyte-derived DC was established using an IL-4/GM-CSF/TriMix maturation cocktail. As shown in previously published data this improves the maturity profile of the DC and improves the T cell stimulatory capacity.Tumor-induced immunosuppression is an important factor hampering the efficacy of immunotherapy. More and more awareness is being raised for this issue. We aimed to map some of the immunosuppressive mechanisms in uterine tumors. To this end, 3 members of the B7 family, B7-H1 (PD-L1), B7-DC (PD-L2) and B7-H4 were analyzed as well as IDO, galectin-1 and galectin-3 as well as the presence and activity of myeloid-derived suppressor cells in uterine tumors. IHC analysis showed that the PD-1:PD-L1 axis and B7-H4 are promising targets in the vast majority of tumors and IDO in a minority of cases. Flow cytometric analysis showed that MDSC do infiltrate uterine tumors and are likely functionally active, thus presenting another route at which tumor immune escape may be interrupted.Beside using active immunotherapeutic regimens or direct intervention of immunosuppression, substances that are used for current anti-cancer treatment may also be averted in a different dosage to modulate the immune system. Low-dose cyclophosphamide, for example, has been shown to have immunomodulatory effects. We verified the effect of oral administration of low-dose cyclophosphamide on the Treg population in order to determine whether or not this modality could be applied for uterine tumors. However, we could not confirm the suppressive effect of cyclophosphamide on Treg. Consequently, this method is according to our results, not applicable in uterine tumors.Taken together, the current research is the next step in the identification of the role the immune system plays in uterine tumors and provides novel indications for its use and its modulation in the treatment of uterine cancer.
Source: Lirias
Author: Vanderstraeten, Anke
Institution: KU Leuven
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Keywords: uterine cancer, dendritic cell vaccine, WT1 mRNA, tumor antigens, MAGE-A3, BORIS, MUC1, Sp17, hTERT, monocyte-derived dendritic cells, dendritic cell maturation, tumor immunosuppression, PD-L1, PD-1, B7-H4, IDO, galectin-1, galectin-3, myeloid-derived suppressor cells, combination immunotherapy
Open Access status: green
OpenAlex ID: W7028648122
